Botanix Investor Centre

Botanix Pharmaceuticals is a clinical stage dermatology company developing novel treatments for common skin diseases and infection leveraging its novel delivery technology, Permetrex™.

Our goal is to unlock the true potential of synthetic cannabinoids for people around the world, with an evidence-first approach. Our shareholders are valued partners in our Company, so we invite you to explore our Investor Centre, subscribe to our email updates and we will keep you updated with our progress.

ASX: BOT | Share price


Change

Feb 4, 2021
April 6, 2017
December 9, 2019
September 17, 2019
January 31, 2019
November 15, 2018
August 13, 2018
April 9, 2018
November 13, 2017

Latest video

Botanix submits NDA for FDA approval of Sofpironium Bromide

Botanix has today announced the submission of a New Drug Application…

Capital Raise Update

Botanix has announced it has now closed the first tranche of…

$7.5m Capital Raise

Botanix has today announced it has received strong commitments…

Research Report by Euroz Hartleys – 17 August 2022

Botanix (ASX:BOT) is pleased to advise that leading adviser…

Euroz Hartleys Report | 7 July 22

Botanix (ASX:BOT) is pleased to share a research report from…

NDA filing accelerated and trials fully enrolled

Botanix has today announced the New Drug Approval (NDA) submission…

Euroz Hartleys Report | 22 June 2022

Botanix (ASX:BOT) is pleased to share a research report from…

Herald Sun + Daily Telegraph | Sofpironium Bromide Story

🗞 MAKING HEADLINES Herald Sun Reporter, Owen Leonard,…

Check out our latest investor presentation

Sign up to receive our latest news

Processing...
Thank you! Your subscription has been confirmed. You'll hear from us soon.
ErrorHere